

BOARD OF DIRECTORS

Minutes of the decisions of 7 January 2021 taken by written procedure  
(EIF Statutes, Article 18(2), Rules of Procedure, Article 8(3))

Seroba Life Sciences Fund IV Limited Partnership

[...]

*Parts of this document may have been redacted if, at the time of the Board's decision, falling under the exceptions for disclosure defined by the EIF Transparency Policy\*, notably under articles 5.4, 5.5 and 5.6.*

\* [http://www.eif.org/news\\_centre/publications/EIF\\_Transparency\\_policy.htm?lang=-en](http://www.eif.org/news_centre/publications/EIF_Transparency_policy.htm?lang=-en)

BOARD OF DIRECTORS

Minutes of the decisions of 7 January 2021 taken by written procedure  
(EIF Statutes, Article 18(2), Rules of Procedure, Article 8(3))

On 17 December 2020, and as anticipated at the Board of Directors ("Board") meeting on 15 December 2020, the SECRETARY submitted the below proposals to the Board for decision by written procedure.

It was noted that, in line with Section 2.2(a) of the Policy for the Use of Written Procedures, the proposals would be considered approved as of 5.00p.m. on 7 January 2021, unless the procedure was interrupted, resulting in the postponement of one or both of the decisions.

At the end of the period, the following decisions were noted:

**21/006      Seroba Life Sciences Fund IV Limited Partnership**

Risk Capital Resources, Pan-European Guarantee Fund – Target Fund Size Facility, own resources

*Pan-European venture capital fund focusing on life sciences investments with a certain focus on Ireland and, to a lesser extent, France, Benelux, the DACH region and the Nordics.*

The Board of Directors approved an investment in Seroba Life Sciences Fund IV Limited Partnership, on the terms and conditions set out in document 21/006.

[...]

Luxembourg, 7 January 2021.

The CHAIRMAN                      *(signed)*

Dario SCANNAPIECO

The SECRETARY                      *(signed)*

Maria LEANDER